Scarica l'app Stockscreener
2.21
0.91%
0.02
Dopo l'orario di chiusura:
2.29
0.08
+3.62%
Precedente Chiudi:
$2.19
Aprire:
$2.2
Volume 24 ore:
136.05K
Relative Volume:
0.84
Capitalizzazione di mercato:
$78.77M
Reddito:
$1.79M
Utile/perdita netta:
$-70.90M
Rapporto P/E:
-0.1422
EPS:
-15.54
Flusso di cassa netto:
$-34.95M
1 W Prestazione:
+7.80%
1M Prestazione:
-28.48%
6M Prestazione:
-41.99%
1 anno Prestazione:
-43.33%
Intervallo 1D:
$2.05
$2.3459
Intervallo di 1 settimana:
$1.98
$2.3459
Portata 52W:
$1.5201
$16.94
Senti Biosciences Inc Stock (SNTI) Company Profile
Nome
Senti Biosciences Inc
Settore
Industria
Telefono
(650) 382-3281
Indirizzo
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Confronta SNTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
2.21 | 78.77M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Senti Biosciences Inc Stock (SNTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-06 | Iniziato | Laidlaw | Buy |
| 2022-10-07 | Iniziato | Morgan Stanley | Equal-Weight |
Senti Biosciences Inc Borsa (SNTI) Ultime notizie
Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener
Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq
FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com
FDA Backs Senti Bio Revolutionary Cancer Drug as 60% of AML Patients Face Critical Outcomes - Stock Titan
Senti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan Capital - Defense World
Senti Biosciences (SNTI) Rating and Price Target Updated by Chardan Capital | SNTI Stock News - GuruFocus
Senti Biosciences Announces New Employment Inducement Grants - The Manila Times
Gene Circuit Pioneer Senti Bio Grants $310K in Stock Options to Expand Next-Gen Therapy Team - Stock Titan
Laidlaw Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc.SNTI - WV News
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. | SNTI Stock News - GuruFocus
Laidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy Recommendation - Nasdaq
SNTI: Senti Biosciences Receives "Buy" Rating from Laidlaw & Co. - GuruFocus
Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC - The Manila Times
Exclusive: Senti Bio Leaders Reveal Next-Gen Cell Therapy Vision in Chardan Fireside Discussion - Stock Titan
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target - GuruFocus
Senti Bio (SNTI) Receives Buy Rating from Laidlaw with $5 Target | SNTI Stock News - GuruFocus
Laidlaw initiates coverage on Senti Biosciences stock with buy rating By Investing.com - Investing.com Nigeria
Laidlaw initiates coverage on Senti Biosciences stock with buy rating - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amerant Bancorp Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti ... - Bluefield Daily Telegraph
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc - ACCESS Newswire
Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise - insights.citeline.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc.GMED - PR Newswire
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc - ACCESS Newswire
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar - The Manila Times
Senti Bio CEO Reveals Next-Gen Gene Circuit Platform: Live Webull Biotech Investment Presentation Coming May 29 - Stock Titan
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Develo - GuruFocus
Senti Bio (SNTI) Secures Additional Funding for SENTI-202 Development | SNTI Stock News - GuruFocus
Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy - Nasdaq
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 - Yahoo Finance
SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com
Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc. - ACCESS Newswire
Senti Biosciences advances AML treatment with SENTI-202 trial By Investing.com - Investing.com Nigeria
Senti Biosciences advances AML treatment with SENTI-202 trial - Investing.com
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 - The Manila Times
Renaissance Technologies LLC Makes New $181,000 Investment in Senti Biosciences, Inc. (NASDAQ:SNTI) - Defense World
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development - The Manila Times
Senti Biosciences Reports Positive Phase 1 Results for SENTI-202 in Acute Myeloid Leukemia Treatment - Nasdaq
Senti Bio Phase 1 Trial Shows 57% Complete Remission Rate in AML Treatment | SNTI Stock News - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI - FinancialContent
Senti Biosciences Inc Azioni (SNTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Senti Biosciences Inc Azioni (SNTI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lu Timothy K | CEO |
Feb 06 '25 |
Sale |
4.36 |
545 |
2,376 |
82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 04 '25 |
Sale |
4.07 |
1,297 |
5,279 |
8,803 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. |
Feb 06 '25 |
Sale |
4.37 |
182 |
795 |
8,621 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):